Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Merck stock slid Tuesday after the company’s earnings failed to ease growing worries about the impending expiration of the ...

UnitedHealth shares continue to struggle after the company issued a fresh outlook for 2025, indicating revenue and adjusted ...

Today, we are on the lookout for more than 170 reports per Nasdaq. Many of them happened this morning. Here were the top 10 reports (by market cap) happening in the A.M. Here are some of the ...

Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced that the first patient has ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

Donald Trump has a lot of thoughts. Most of them don't make any sense, and the sentences themselves are often barely ...

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, ...

The money will focus on a manufacturing plant in Virginia that will make the company's weight management and metabolic drugs ...

Omega Fund VIII, was oversubscribed and beat its $600 million target, reaching the hard cap. With Fund VIII, the firm will continue to execute its strategy of creating and investing in life sciences ...

Commerce Secretary Howard Lutnick said Trump's new tariff policies are focused on ending the U.S.'s reliance on foreign supply of key pharmaceutical products. "We are proud that AstraZeneca has made ...